Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer

We sought to characterise whether dexamethasone (DEX) may enhance tumour response to docetaxel in in vitro and in vivo models of metastatic prostate cancer (CaP). In vitro experiments conducted on PC3 and human bone marrow endothelial cells (hBMECs) determined that administration of DEX (10 nM) redu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, C, Scullin, P, Worthington, J, Seaton, A, Maxwell, P, O'Rourke, D, Johnston, P G, McKeown, S R, Wilson, R H, O'Sullivan, J M, Waugh, D J J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607236/
https://www.ncbi.nlm.nih.gov/pubmed/19050703
http://dx.doi.org/10.1038/sj.bjc.6604804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607236/
https://www.ncbi.nlm.nih.gov/pubmed/19050703
http://dx.doi.org/10.1038/sj.bjc.6604804

Ejemplares similares